

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# **FOSUN PHARMA**

## **复星医药**

上海復星醫藥（集團）股份有限公司

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

- (1) RE-APPOINTMENT OF CHAIRMAN AND VICE CHAIRMAN**
- (2) APPOINTMENT OF CO-CHAIRMAN**
- (3) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND  
CO-CHIEF EXECUTIVE OFFICER AND**
- (4) CHANGE IN BOARD COMMITTEE COMPOSITION**

The Board is pleased to announce that the following board resolutions have been passed with effect from 1 June 2022:

- (1) Mr. Wu Yifang has been re-appointed as the chairman of the ninth session of the Board;
- (2) Mr. Wang Kexin has been appointed as the co-chairman of the ninth session of the Board;
- (3) Ms. Guan Xiaohui has been re-appointed as the vice chairman of the ninth session of the Board;
- (4) Mr. Wen Deyong has been appointed as the chief executive officer of the Company;
- (5) Mr. Chen Yuqing has been appointed as the co-chief executive officer of the Company; and
- (6) Mr. Wu Yifang has been appointed as the chairman of the strategic committee of the ninth session of the Board.

### **RE-APPOINTMENT OF CHAIRMAN**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Wu Yifang has been re-appointed as the chairman of the ninth session of the Board with effect from 1 June 2022.

## **APPOINTMENT OF CO-CHAIRMAN**

The Board is pleased to announce that Mr. Wang Kexin has been appointed as the co-chairman of the ninth session of the Board with effect from 1 June 2022.

## **RE-APPOINTMENT OF VICE CHAIRMAN**

The Board is pleased to announce that Ms. Guan Xiaohui has been re-appointed as the vice chairman of the ninth session of the Board with effect from 1 June 2022.

## **APPOINTMENT OF CHIEF EXECUTIVE OFFICER**

Due to the adjustment of work arrangement, Mr. Wu Yifang ceases to serve as the chief executive officer of the Company with effect from 1 June 2022 but remains as the executive Director and the chairman of the Board. At the same time, the Board is pleased to announce that Mr. Wen Deyong has been appointed as the chief executive officer of the Company for a period of three years with effect from 1 June 2022 until the expiration of the current term of the Board.

Mr. Wu Yifang has confirmed that he has no disagreement with the Board and there are no other matters relating to his cessation as the chief executive officer of the Company that needs to be brought to the attention of the Shareholders. The Company would like to express its gratitude to Mr. Wu Yifang for his contribution to the Company during his tenure as the chief executive officer of the Company.

## **APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER**

The Board is pleased to announce that Mr. Chen Yuqing has been appointed as the co-chief executive officer of the Company for a period of three years with effect from 1 June 2022 until the expiration of the current term of the Board. By reference to his responsibilities and accountability structure, the co-chief executive officer of the Company is not a chief executive as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

## **CHANGE IN BOARD COMMITTEE COMPOSITION**

The Board is pleased to announce that Mr. Wu Yifang has been appointed as the chairman of the strategic committee of the ninth session of the Board with effect from 1 June 2022. Mr. Chen Qiyu no longer serves as the chairman of the strategic committee but remains as a member of the strategic committee with effect from 1 June 2022. Save as disclosed above, the appointments of the members of the Board committees of the ninth session remain the same as those of the eighth session of the Board.

## INFORMATION REQUIRED TO BE DISCLOSED PURSUANT TO RULE 13.51(2) OF THE LISTING RULES

### Biographical Details of Mr. Wang Kexin (王可心先生)

Mr. Wang Kexin (王可心), aged 58, is an executive Director and the co-chairman of the Board and is a director of certain subsidiaries of the Group. He joined the Group in June 2010 and served as the vice president of the Company from July 2011 to July 2016, a senior vice president of the Company from July 2016 to October 2020 and the co-president and chief investment officer of the Company from October 2020 to January 2022, has served as an executive Director since December 2021, served as a vice chairman of the Company from January 2022 to June 2022, and has served as the co-chairman of the Company since June 2022. He is currently a vice president of Fosun International Limited (stock code: 00656), a company listed on the The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”). Prior to joining the Group, he served as the deputy general manager of Haihong Holdings Pharmaceutical E-commerce Co., Ltd.\* (海虹控股醫藥電子商務有限公司), the marketing director of Kunming Pharmaceutical (Group) Co., Ltd.\* (昆明製藥集團股份有限公司) (stock code: 600422), a company listed on Shanghai Stock Exchange, the general manager of Kunming Pharmaceutical Sales Co., Ltd.\* (昆明製藥藥品銷售有限公司), the general manager of Beijing Huali Jiuzhou Pharmaceutical Co., Ltd.\* (北京華立九州醫藥有限公司), the vice president of Chongqing Huali Pharmaceutical Co., Ltd.\* (重慶華立藥業股份有限公司) (previous stock code: 000607), a company previously listed on Shenzhen Stock Exchange, and the chairman of Beijing Tianren Hexin Pharmaceutical Management Co., Ltd.\* (北京天仁合信醫藥經營有限責任公司). He obtained a bachelor’s degree in pharmacy from Shenyang Pharmaceutical College.

The remuneration to be received by Mr. Wang Kexin as an executive Director is determined based on the executive Director appraisal program approved by the Shareholders at the annual general meeting held on 1 June 2022. For the year ended 31 December 2021, Mr. Wang Kexin received remuneration amounting to RMB7.1879 million (before tax) from the Group in his capacity as a senior management. The relevant Director service contract between Mr. Wang Kexin and the Company does not provide for the specific amount of the remuneration.

Mr. Wang Kexin has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any Directors, senior management or substantial Shareholders of the Company, did not hold any other positions with the Company or any of its subsidiaries, and did not hold any other directorships in listed companies in the last three years.

To the knowledge of the Directors, as at the date of this announcement, Mr. Wang Kexin has personal interests in 202,500 domestic shares of the Company (“**A Shares**”) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”), representing approximately 0.01% of the Company’s total number of issued A Shares and approximately 0.01% of the total number of issued shares of the Company. Save as disclosed above, Mr. Wang Kexin does not or is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any other matters relating to the appointment of Mr. Wang Kexin as the co-chairman of the Board that need to be brought to the attention of the Shareholders.

### **Biographical Details of Mr. Wen Deyong (文德鏞先生)**

Mr. Wen Deyong (文德鏞先生), aged 50, is currently the chief executive officer of the Company and holds directorships and management positions in certain subsidiaries of the Company. Mr. Wen Deyong joined the Group in May 2002 and had worked in Chongqing Yaoyou Pharmaceutical Co., Ltd., a subsidiary of the Company, for an extended period, successively serving as the general manager of the second marketing department, vice president, president and vice chairman, etc. He served as the vice president of the Company from June 2016 to October 2020, the senior vice president of the Company from October 2020 to January 2022, the co-president of the Company from January 2022 to April 2022, the president of the Company from April 2022 to June 2022, and has served as the chief executive officer of the Company since June 2022. Mr. Wen Deyong is currently a non-executive director of Sinopharm Group Co. Ltd., a company listed on the Hong Kong Stock Exchange (stock code: 01099), a director of China National Medicines Corporation Ltd., a company listed on the Shanghai Stock Exchange (stock code: 600511), and the chairman of the supervisory committee of China National Accord Medicines Corporation Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 000028). Mr. Wen Deyong was a director of C.Q. Pharmaceutical Holding Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 000950), and a director of Anhui Sunhere Pharmaceutical Excipients Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 300452). Prior to joining the Group, Mr. Wen Deyong worked in Chongqing Pharmaceutical Co., Ltd. 6th Factory (the predecessor of Chongqing Yaoyou Pharmaceutical Co., Ltd.). Mr. Wen Deyong graduated from West China University of Medical Science (currently West China Medical Center, Sichuan University) majoring in pharmacy and holds a master's degree in business administration from Donghua University.

The remuneration to be received by Mr. Wen Deyong as the chief executive officer is determined by the Board on a combined basis of various factors, such as corporate economic efficiency, the duties of his position, actual performance and with reference to the external industry remuneration standards. As at the date of this announcement, the Company and Mr. Wen Deyong have not yet finalized the specific amount of the remuneration for the chief executive officer.

Mr. Wen Deyong has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any Directors, senior management or substantial Shareholders of the Company, did not hold any other positions with the Company or any of its subsidiaries, and did not hold any other directorships in listed companies in the last three years.

To the knowledge of the Directors, at the date of this announcement, Mr. Wen Deyong does not or is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any other matters relating to the appointment of Mr. Wen Deyong as the chief executive officer of the Company that need to be brought to the attention of the Shareholders.

By order of the Board  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***  
**Wu Yifang**  
*Chairman*

Shanghai, the PRC  
1 June 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin and Ms. Guan Xiaohui; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi, and Mr. Yu Tze Shan Hailson.*

\* *For identification purposes only*